Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huiren Shenbao is a prominent Traditional Chinese Medicine (TCM) product developed and manufactured by the Huiren Group. It is formulated as a complex mixture of 22 medicinal herbs, including *Panax ginseng*, *Epimedium brevicornu*, *Cistanche deserticola*, *Astragalus membranaceus*, and *Rehmannia glutinosa*. The product is primarily indicated for the treatment of "kidney deficiency" (Shenxu) according to TCM theory, which manifests as symptoms such as lower back pain, knee weakness, fatigue, dizziness, and sexual dysfunction (including impotence and premature ejaculation). It is officially approved in China as an over-the-counter (OTC) medication and is available in multiple dosage forms, most notably tablets (Shenbao Pian) and oral solutions (Shenbao Heji). The formulation is designed to tonify the kidney yang, replenish kidney essence, and regulate the body's overall physiological balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huiren Shenbao.